Gene therapies are very important in the early stages of development, so it would be sensible to keep tabs of patients with changes in the innovative CRISPR technique. For some scientists in China, however, it is apparently not a priority.
According to The Wall Street Journal, the number of Chinese cancer patients is not safe. In these cases, patients underwent the genetic tool CRISPR-Cas9 gene-editing in an attempt to treat their genes. At least one scientist at a test did not maintain links with patients and conducted follow-up studies, according to WSJ.
In fact, the follow-ups are extremely critical for patients with gene therapy. DNA changes can lead to inappropriate effects known as knockout effects. The supposed health problems that arise from genetic changes, such as autoimmune disorders, would appear later.
"Because we do not understand the human genome completely and we are still developing our knowledge [CRISPR-Cas9 and related technologies]We have to control the whole life of the patients and their unintended consequences, "said Jennifer Doudna, a biochemist at Berkeley from California University and the inventor of CRISPR, said WSJ.
It is a sustainable development in biomedical research in China. Last month, scientist He Jiankui produced the world's first gene-edited babies. Scientist working at the Southern University of Science and Technology, Shenzhen CRISPR used to change the DNA of human embryos as a result of the birth of the liver victims due to their immune against HIV. After this news, the Chinese government expanded its social credit system to avoid breaking the researchers.
The introduction of the genetic genes of the human genome and the implantation of the embryo into the mother's womb is not legal in China, or elsewhere, especially since the genre edition has begun and the legacy of the changed characteristics are inheritable (in the United States and China in the United States, the embryo is changing, but nowadays some must pass after destroying them). Editing somatic genes, on the other hand, modifies the DNA of a living person to treat various diseases, cancer and haemophilia, and are not inheritable genetic modifications. But somatic gene therapy, like the germinate variety, is in childhood, which requires diligence, careful negligence and careful care.
Somatic gene therapies are legal in China and the United States. In the United States, research scientists are focusing attention and trepidation in the direction that the Food and Drug Association maintains with a rigorous look. Until now, only one gene therapy has been approved in the United States, in the University of Pennsylvania, to test CRISPR safety and among 18 patients.
China Already Gen-edited with 86 people with CRISPR
In the United States, the first clinical trials of the CRISPR genes are planned. China, on the other hand, has made headway in the use of genetic DNA modification tools in clinical trials of DNA in several decades.
In China, however, the FDA does not work. Doctors may follow a clinical trial after accepting hospital ethics committees, WSJ reports. Since January 2018, at least 86 Chinese patients have been published with CRISPR DNA. Most trials are being carried out by Anhui Kedgene Biotechnology Co, a private startup, as the WSJ states:
Kedgene's project has touched on the patients who have changed DNA in patients, according to the person who is familiar with the topic. Kedgene's founder, Mandy Zhou, said a trial was not in accordance with the planned outcome, and as a result, patients touched on it. Patients were not treated during this trial, he added.
Other Kedgene trial in the Anhui Province Hospital treated 18 patients, according to Wang Yong. Many participants were killed as cancer, Dr. Wang said without giving a specific number. Dr. Wang was asked by the ministry of science this month to send a trial report for the first time since the Beijing authorities requested information more than a year ago.
The three doctors who participated in the gene screening sessions were contacted by the Ministry of Science and Health of China (although the FDA is not very close). For more information on WSJ's contact with these ministries, they have commented.
This is very frustrating and miserable, especially this deplorable scientific behavior giving a complete overview of CRISPR and the bad name genre editing. CRISPR and other gene-editing technologies are ready to eradicate the results of diseases and should be launched during the selection and improvement of human characteristics (gene-edited twins, who are immune to AIDS virus, for example, is a very good idea in principle, too early.
Unfortunately, the situation of Chinese scientists gains public opinion against biotechnology that is currently controversial.[The Wall Street Journal]